The microbiome of colorectal cancer patients at Tishreen University Hospital and Oncology Center: a focus on Fusobacterium nucleatum

Rapid detection of fadA in Fusobacterium nucleatum by the quantitative loop-mediated isothermal amplification colorimetric-phenol red method: a case control study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN53358464

Enrollment

500

Registered

2023-08-29

Start date

2019-10-16

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer Cancer

Interventions

QLAMP-PR assays were tested on about 500 stool samples (250 CRC patients, 250 healthy controls) specifically for the FadA gene of F.nucleatum. Six primers were designed and synthesized with master mix

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CRC patients: 1. Accepted in Tishreen Hospital-chemotherapy center 2. Individuals diagnosed with CRC between 11/2019 and 11/2020 3. Confirmation of the diagnosis through pathology reports. 4. Any CRC stage or grade 5. Has or hasn't had chemotherapy or colon surgery Healthy controls: 1. Individuals without a history of colorectal cancer or colon polyps 2. Individuals without a history of any chronic bowel diseases (IBD, crown, IBS, ..) or any Gastrointestinal complaint (diarrhea, jaundice, hemorrhoids, bacterial enteritis, heartburn) for at least 3 weeks prior to the study sampling 3. Similar demographic characteristics to the patient group to minimize confounding factors.

Exclusion criteria

Exclusion criteria: CRC patients: 1. Individuals with a history of other cancers to maintain a homogeneous study population 2. Patients with a known genetic predisposition to colorectal cancer 3. Have had pre-sampling radiation therapy 4. Used antibiotics for at least 3 weeks prior to the study sampling Healthy controls: 1. Individuals with a personal history of any cancer to maintain a cancer-free control group 2. Individuals with a family history of colorectal cancer in first-degree relatives 3. Used antibiotics for at least 3 weeks prior to the study sampling 4. Used antacid or PPIs drugs for at least 3 weeks prior to the study sampling

Design outcomes

Primary

Measure	Time frame
A digital value of the F. nucleatum DNA copy number amount (or concentration with ng/ul) measured by LAMP protocol using a visible spectrophotometer at 420 nm, 500 nm and 560 nm at baseline and 1, 2, 3, 4 weeks	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Syria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 8, 2026